Smell is one of the most complex and least understood senses, and that is exactly why “regaining smell” is so hard. It is not like vision or hearing where the pathways and failures are often easier to map. In smell, the system is distributed, chemical, and deeply tied to the brain’s interpretation, which makes it both scientifically fascinating and clinically frustrating.

That complexity is also why the scientists featured by Scientific American are working on restoring smell in the first place. If the sense is still a black box, then any credible attempt to regain it has to do two things at once: identify what broke, and then rebuild enough of the functional pathway for smell to return. The goal is not just “more detection.” The goal is a usable sense of smell that supports everyday life, including taste, food experience, and safety signals that many people take for granted until they disappear.

From a business and governance standpoint, the interesting part is the translation challenge. A lot of medical innovation starts with something measurable, then moves toward something meaningful. With smell, the measurement itself is a hurdle because the sense is both sensitive and context-dependent, and because “smelling” is not just an input event. It is the brain turning odor chemistry into perception. That means therapies, devices, or interventions must be evaluated on outcomes that reflect real function, not just lab signals.

There is also an incentive problem that can quietly derail projects like this. Boards and investors generally want programs to de-risk uncertainty early, but smell restoration sits in the zone where scientific uncertainty is high. Scientific American’s framing, that smell is complex and least understood, is a direct warning label for anyone expecting a quick, linear path from mechanism to market. Programs here tend to benefit from staged milestones: first show the biology can be influenced, then show that influence can translate into consistent perceptual improvement across patients.

Regulatory context matters too, even when a story does not name specific agencies or pathways. In general, therapies that aim to restore function must demonstrate not only safety, but clinical benefit that is specific enough to satisfy regulators and convincing enough for clinicians to adopt. For smell, that usually implies clear endpoints, patient-relevant improvement, and reproducibility across different causes of smell loss. The “least understood” part of the science is not just an academic description, it is a practical one: regulators and trial designers will demand evidence that the intervention changes outcomes in a way that holds up across time and variability.

Now zoom out to second-order implications, because smell programs do not only impact patients. They also shape adjacent markets like diagnostic testing, neuro-olfactory research tools, and the broader category of sensory and neurological therapeutics. If smell restoration becomes tractable, it can unlock new cohorts, new study designs, and new commercial pathways. If it stays elusive, spending may consolidate toward easier-to-quantify targets. In other words, the complexity described by Scientific American is a sorting mechanism for capital and attention.

For decision-makers watching from the sidelines, the strategic stake is straightforward: smell dysfunction is a real patient problem, but converting that reality into reliable interventions requires better science. That is why the work highlighted by Scientific American is worth tracking. Any progress toward regaining smell is not just a breakthrough for individuals who lost it. It is proof that one of the body’s most complicated sensory systems can be partially repaired, and that could change how similar neurological and sensory programs are evaluated, funded, and scaled.